NEWS ACCESS BIO
Total 19
Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron
Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron

Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron

(2021.12.08)
 Based on sequence analysis and Omicron recombinant protein test, Omicron variant does not have influence on the target region of CareStart™ COVID-19 Rapid and PCR Tests.
ANNOUNCEMENT OF THE RECORD DATE FOR DETERMINING SHAREHOLDERS
ANNOUNCEMENT OF THE RECORD DATE FOR DETERMINING SHAREHOLDERS

ANNOUNCEMENT OF THE RECORD DATE FOR DETERMINING SHAREHOLDERS

(2020.12.14)
 In accordance with Article 16 (1) of the “Korean Depository Receipt Agreement” signed between Access Bio and Korea Securities Depository on March 11, 2013, the Record Date for determining shareholders in 2020 is December 31, 2020.
CONCORDANCE HEALTHCARE SOLUTIONS AND NDC INK NATIONAL DISTRIBUTION AGREEMENTS
CONCORDANCE HEALTHCARE SOLUTIONS AND NDC INK NATIONAL DISTRIBUTION AGREEMENTS

CONCORDANCE HEALTHCARE SOLUTIONS AND NDC INK NATIONAL DISTRIBUTION AGREEMENTS

(2020.12.03)
 Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US
FDA GREENLIGHTS ACCESS BIO’S 10-MINUTE COVID-19 ANTIGEN TEST
FDA GREENLIGHTS ACCESS BIO’S 10-MINUTE COVID-19 ANTIGEN TEST

FDA GREENLIGHTS ACCESS BIO’S 10-MINUTE COVID-19 ANTIGEN TEST

(2020.10.13)
 Emergency Use Authorization Granted for CareStartTM Point-Of-Care Kit
CARESTART™ IGM/IGG ANTIBODY TEST GRANTED EUA AUTHORIZATION
CARESTART™ IGM/IGG ANTIBODY TEST GRANTED EUA AUTHORIZATION

CARESTART™ IGM/IGG ANTIBODY TEST GRANTED EUA AUTHORIZATION

(2020.08.04)
 Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Serology Test Capable of Determining Subjects’ past COVID-19 Exposure and Immunoresponse within 10 Minutes
THE NEWEST ASSET IN THE FIGHT AGAINST COVID-19
THE NEWEST ASSET IN THE FIGHT AGAINST COVID-19

THE NEWEST ASSET IN THE FIGHT AGAINST COVID-19

(2020.07.15)
 Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Molecular Test that May Provide Laboratories Results in 83 Minutes or Less
GETTING TESTS WHERE THEY’RE NEEDED MOST
GETTING TESTS WHERE THEY’RE NEEDED MOST

GETTING TESTS WHERE THEY’RE NEEDED MOST

(2020.07.12)
 Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.
THE GOAL: ENDING MALARIA IN OUR LIFETIME
THE GOAL: ENDING MALARIA IN OUR LIFETIME

THE GOAL: ENDING MALARIA IN OUR LIFETIME

(2020.06.20)
 Malaria and its effects are primarily concentrated in poor, developing nations. in 2018, there were an estimated 228 million cases around the world and more than 400,000 deaths. Of those, more than 90% of cases and mortalities occurred in the sub-Saharan region of Africa, and children under the age of 5 account for two-thirds of all malaria deaths worldwide.
IN PARTNERSHIP WITH THE GLOBAL GOOD
IN PARTNERSHIP WITH THE GLOBAL GOOD

IN PARTNERSHIP WITH THE GLOBAL GOOD

(2020.02.18)
 New rapid diagnostic test now available to research organizations for low parasitemia settings
Powered by KBoard